FDA approves Lilly osteoporosis drug

December 17, 1997

A new drug developed by Eli Lilly for the prevention of osteoporosis has been approved by the Food and Drug Administration. The drug, called Evista (raloxifene hydrochloride), will compete with Merck's Fosamax treatment, as well as estrogen-replacement

A new drug developed by Eli Lilly for the prevention of osteoporosis has been approved by the Food and Drug Administration. The drug, called Evista (raloxifene hydrochloride), will compete with Merck's Fosamax treatment, as well as estrogen-replacement therapies such as Premarin from American Home Products.